Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
161
-
Total 13F shares, excl. options
-
75.9M
-
Shares change
-
+5.08M
-
Total reported value, excl. options
-
$1.97B
-
Value change
-
+$139M
-
Put/Call ratio
-
0.35
-
Number of buys
-
115
-
Number of sells
-
-47
-
Price
-
$26.00
Significant Holders of CG Oncology, Inc. - Common Stock (CGON) as of Q2 2025
187 filings reported holding CGON - CG Oncology, Inc. - Common Stock as of Q2 2025.
CG Oncology, Inc. - Common Stock (CGON) has 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75.9M shares
of 76.6M outstanding shares and own 99.15% of the company stock.
Largest 10 shareholders include Decheng Capital LLC (6.37M shares), VANGUARD GROUP INC (5.91M shares), BlackRock, Inc. (4.46M shares), FMR LLC (3.86M shares), TCG Crossover Management, LLC (3.67M shares), BRAIDWELL LP (3.28M shares), Kynam Capital Management, LP (2.46M shares), UBS Group AG (2.23M shares), Foresite Capital Management VI LLC (2.22M shares), and STATE STREET CORP (2.17M shares).
This table shows the top 161 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.